Trial reportJournal of clinical hypertension (Greenwich, Conn.)2004
Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03738761 (Fixed-Dose Combination of Perindopril/Amlodipine), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials.BMC nephrology · 2013Pooled it
- Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study.Clinical drug investigation · 2009Trial
- Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.Clinical drug investigation · 2008Trial
- Comparative Solid-State Stability of Perindopril Active Substance vs. Pharmaceutical Formulation.International journal of molecular sciences · 2017Article
- RAAS inhibition and mortality in hypertension.Global cardiology science & practice · 2013Review
- Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.BMC cardiovascular disorders · 2010Article
- Perindopril: the evidence of its therapeutic impact in hypertension.Core evidence · 2007Article
- Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors.Journal of clinical hypertension (Greenwich, Conn.) · 2005Article
- Angiotensin-converting enzyme inhibitor use in the year 2005.Journal of clinical hypertension (Greenwich, Conn.) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.